Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA. We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.
Tewksbury, US
Size (employees)
54 (est)
Mitralign was founded in 2003 and is headquartered in Tewksbury, US
Report incorrect company information

Key People/Management at Mitralign

Rick Geoffrion

Rick Geoffrion

Richard J. Omilanowicz

Richard J. Omilanowicz

Adam Groothuis

Adam Groothuis


Mitralign Office Locations

Mitralign has an office in Tewksbury
Tewksbury, US (HQ)
2 3 Highwood Dr
Show all (1)
Report incorrect company information

Mitralign Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$135.2 m

Latest funding size

$39.80 m

Time since last funding

2 years ago


Mitralign's latest funding round in May 2016 was reported to be $39.8 m. In total, Mitralign has raised $135.2 m
Show all financial metrics
Report incorrect company information